Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Staci Ward

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Dermatology (Basel, Switzerland)|February 20, 2003
Bexarotene is a new treatment option for lymphomatoid papulosisRichard A Krathen, Staci Ward, Madeleine Duvic
Leukemia & Lymphoma|March 23, 2002
Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK)Rakhshandra Talpur, Narin Apisarnthanarax, Staci Ward, et al.
Journal of the American Academy of Dermatology|October 26, 2002
Optimizing bexarotene therapy for cutaneous T-cell lymphomaRakhshandra Talpur, Staci Ward, Narin Apisarnthanarax, et al.
Journal of the American Academy of Dermatology|March 23, 2004
Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot studyNarin Apisarnthanarax, Rakhshandra Talpur, Staci Ward, et al.
The Journal of Investigative Dermatology|November 25, 2003
Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene applicationMadeleine Duvic, Xiao Ni, Rakhashandra Talpur, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Dermatology (Basel, Switzerland)|February 20, 2003
Bexarotene is a new treatment option for lymphomatoid papulosisRichard A Krathen, Staci Ward, Madeleine Duvic
Leukemia & Lymphoma|March 23, 2002
Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK)Rakhshandra Talpur, Narin Apisarnthanarax, Staci Ward, et al.
Journal of the American Academy of Dermatology|October 26, 2002
Optimizing bexarotene therapy for cutaneous T-cell lymphomaRakhshandra Talpur, Staci Ward, Narin Apisarnthanarax, et al.
Journal of the American Academy of Dermatology|March 23, 2004
Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot studyNarin Apisarnthanarax, Rakhshandra Talpur, Staci Ward, et al.
The Journal of Investigative Dermatology|November 25, 2003
Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene applicationMadeleine Duvic, Xiao Ni, Rakhashandra Talpur, et al.
Pageof 1